Takeda Pharmaceutical Co ADR [TAK] stock is trading at $14.65, up 0.76%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The TAK shares have gain 2.16% over the last week, with a monthly amount drifted -3.49%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Takeda Pharmaceutical Co ADR [NYSE: TAK] stock has seen the most recent analyst activity on April 02, 2025, when Morgan Stanley upgraded its rating to a Overweight. Previously, BofA Securities upgraded its rating to Buy on March 16, 2023, and kept the price target unchanged to $20. On July 19, 2022, upgrade upgraded it’s rating to Outperform and revised its price target to $24 on the stock. Morgan Stanley downgraded its rating to a Equal-Weight. JP Morgan downgraded its rating to a Neutral. Cowen started tracking with a Market Perform rating for this stock on November 01, 2019, and assigned it a price target of $19.50. In a note dated August 15, 2019, Daiwa Securities downgraded an Neutral rating on this stock.
Takeda Pharmaceutical Co ADR [TAK] stock has fluctuated between $12.57 and $15.37 over the past year. Takeda Pharmaceutical Co ADR [NYSE: TAK] shares were valued at $14.65 at the most recent close of the market.
Analyzing the TAK fundamentals
Takeda Pharmaceutical Co ADR [NYSE:TAK] reported sales of 30.22B for the trailing twelve months, which represents a drop of -0.06%. Gross Profit Margin for this corporation currently stands at 0.55% with Operating Profit Margin at 0.1%, Pretax Profit Margin comes in at 0.05%, and Net Profit Margin reading is 0.05%. To continue investigating profitability, this company’s Return on Assets is posted at 0.01, Equity is 0.03 and Total Capital is 0.04. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.65.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.60 points at the first support level, and at 14.54 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.72, and for the 2nd resistance point, it is at 14.78.
Ratios To Look Out For
For context, Takeda Pharmaceutical Co ADR’s Current Ratio is 1.31. Also, the Quick Ratio is 0.72, while the Cash Ratio stands at 0.24. Considering the valuation of this stock, the price to sales ratio is 1.54, the price to book ratio is 0.98 and price to earnings (TTM) ratio is 34.45.
Transactions by insiders
Recent insider trading involved Giles Richard Platford, President, Plasma-Derived Ther, that happened on Aug 23 ’24 when 19073.0 shares were purchased.
